Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer
- Conditions
- on-Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2018-001772-38-CZ
- Lead Sponsor
- AbbVie Deutschland GmbH & Co. KG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 310
• Histologically confirmed non-small cell lung cancer (NSCLC) with known non squamous epidermal growth factor receptor (EGFR) status (wild type or mutant; with site documented status).
• Has locally advanced or metastatic NSCLC.
• Has c-Met+ NSCLC as assessed by an AbbVie designated immunohistochemistry (IHC) laboratory. Subject must submit archival or fresh tumor material for assessment of c-Met levels during the pre-screening period. If archival tissue is c-Met negative, fresh biopsy material may be submitted for reassessment of c-Met expression.
•If a subject meets eligibility criteria for c-Met protein expression level based on archival tumor material, fresh tumor material for assessment of c-Met expression levels should be submitted prior to dosing of telisotuzumab vedotin. If it is determined that a biopsy is not appropriate for a given subject, the subject may still be enrolled following investigator consultation with, and confirmation from, AbbVie.
• Subjects who have progressed on systemic cytotoxic chemotherapy (or are ineligible for systemic cytotoxic chemotherapy) and an immune checkpoint inhibitor (as monotherapy or in combination with systemic cytotoxic chemotherapy, or ineligible for an immune checkpoint inhibitor), and prior anti-cancer therapies targeting driver gene alterations (if applicable).
• Subject must have received no more than 2 lines of prior systemic therapy (including no more than 1 line of prior systemic cytotoxic chemotherapy) in the locally advanced or metastatic setting.
• Subjects should not have received prior cMET-targeted antibody therapies.
• Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.
• No known active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. If a subject has signs/symptoms suggestive of SARS-CoV-2 infection, the subject must have a negative molecular (e.g., polymerase chain reaction [PCR]) test result. In addition, if based on the answers to the SARS-CoV-2 Infection Risk Assessment Tool the site considers the subject currently at risk for developing SARS-CoV-2 infection, then the subject should either be tested or advised to come back for study screening after 14 days.
Subjects who do not meet the above COVID-19SARS-CoV-2 infection eligibility criteria must be screen failed and may only rescreen after they meet the COVID-19SARS-CoV-2 infection viral clearance criteria.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 155
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 155
• Has adenosquamous histology.
• Has received anti-cancer therapy including chemotherapy, radiation therapy, immunotherapy, biologic, or any investigational therapy as described in the protocol.
• Subjects with metastases to the central nervous system (CNS) are eligible only after definitive therapy (such as surgery or radiotherapy) is provided and:
? - There is no evidence of progression of CNS metastases at least 4 weeks after definitive therapy.
? - They are asymptomatic and off or on a stable or reducing dose of systemic steroids and/or anticonvulsants for at least 2 weeks prior to first dose of telisotuzumab vedotin.
• Has a clinically significant condition(s) described in the protocol.
• Has unresolved clinically significant adverse events >= grade 2 from prior anticancer therapy, except for alopecia or anemia.
• Had major surgery within 21 days prior to the first dose of telisotuzumab vedotin.
• Subject must not have a history of interstitial lung disease or pneumonitis that required treatment with systemic steroids.
• Subjects must not have any evidence of pulmonary fibrosis on screening imaging assessment or any history of pneumonitis or interstitial lung disease within 3 months of the planned first dose of the study drug.
• Subjects must not have received radiation therapy to the lung <6 months prior to the first dose of telisotuzumab vedotin.
• Subjects must not have received any live vaccine within 30 days of the first dose of investigational product.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: The primary objective is to determine the overall response rate (ORR) of telisotuzumab vedotin in subjects with c-Met+ NSCLC.;Secondary Objective: The secondary objectives are to determine Duration of response (DoR), Disease control rate (DCR), Duration of disease control (DDC), Progression Free Survival (PFS), Overall Survival (OS), Safety and Tolerability.;Primary end point(s): Overall Response Rate (ORR) ;Timepoint(s) of evaluation of this end point: Overall response rate assessed by an independent central review according to RECIST, version 1.1.10 ORR will be defined as the proportion of subjects with a confirmed complete response (CR) or confirmed partial response (PR) based on RECIST, version 1.1.
- Secondary Outcome Measures
Name Time Method Secondary end point(s): 1. Duration of Response (DoR) <br>2. Disease Control Rate (DCR)<br>3. Progression-Free Survival (PFS)<br>4. Overall Survival (OS);Timepoint(s) of evaluation of this end point: 1. Time from subject's initial response (CR or PR) to first occurrence of radiographic progression determined by an independent central review (ICR) or death from any cause for the responders. <br>2. Percentage of subjects with best overall response of confirmed CR or PR, or stable disease (SD) for at least 12 weeks (2 tumor assessments) following enrollment, based on RECIST version 1.1.<br>3. Time from subject's first dose of study drug until first occurrence of radiographic progression determined by an independent central review or death from any cause. <br>4. Time from subject's first dose of study drug until death from any cause.